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WHAT THIS PAPER ADDS
 In our study, we reviewed 150 young patients with peripheral arterial obstructive disease (PAOD) but not Buerger’s disease and
assessed the aetiologies, risk proﬁles and surgical outcomes. Though it was a retrospective study, it represents one of the largest
series of premature PAOD in which thrombophilia was consecutively assessed. The key ﬁnding was that patients with thrombo-
philia had the worst prognosis and that they neededmore re-interventions than patients with undisturbed coagulation. The results
encourage vascular specialists to screen carefully and pay more attention to medical therapy for thrombophilia to get better long-
term patency for these patients.a r t i c l e i n f o
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Objective: To evaluate aetiology proﬁle and role of thrombophilia in patients with premature peripheral
arterial obstructive disease (PAOD) in China.
Methods: Between January 2000 and January 2010, among 368 patients presenting with PAOD, but not
Buerger’s disease, at an age of less than 45 years, 150 patients have been screened for thrombophilia and
the data analysed retrospectively. Aetiologies of thrombophilia which involved in premature PAOD were
assessed and surgical outcomes were stratiﬁed for presence of thrombophilia.
Results: In 57 of 150 patients (38%), laboratory assay results suggested thrombophilia, and the rest of
them presented with other aetiology (62%). A total of 108 patients, including 38 patients with throm-
bophilia (35%), needed some type of revascularisation. At 30 days, recurrent thrombosis (29% vs. 9%;
p ¼ 0.005) and major amputations (11% vs. 1%; p ¼ 0.032) were more common in patients with
thrombophilia. At 1 year, primary patency (56% vs. 75%, p ¼ 0.043), secondary patency (68% vs. 92%,
p ¼ 0.036) and limb salvage (74% vs. 96%, p ¼ 0.038) were signiﬁcantly lower in patients with
thrombophilia.
Conclusion: Thrombophilia is frequently diagnosed among premature PAOD in China and adversely
affects outcome after revascularisation. Clinicians should be aware of its high prevalence and aim at
screening and sustained thrombophilia treatment.
Crown Copyright  2012 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery. All
rights reserved.d as a Poster presentation at
Surgery (SVS), Boston, USA,
: þ86 10 69158231.
012 Published by Elsevier Ltd onPeripheral arterial obstructive disease (PAOD) is commonly
associated with atherosclerotic arterial lesions that occur within
the context of typical cardiovascular risk factors such as arterial
hypertension, hyperlipidaemia, diabetes mellitus and smoking in
an elderly population.1 However, in some patients, symptomatic
PAOD is diagnosed before the age of 45 years and is not associated
with such obvious risk factors.2 Thus, aetiology of premature PAODbehalf of European Society for Vascular Surgery. All rights reserved.
Table 1
Aetiology proﬁle of premature PAOD in 150 young Chinese adults.
Aetiology or risk factors n %
Thrombophilia 57 38.0
Hypercoagulable states 33 22.0
Hyperhomocysteinemia 14 9.3
PC/PS deﬁciency 6 2.0
Eosinophiliaa 7 4.7
Polycythemiavera 1 0.7
Acutemyelocytic leukaemia 1 0.7
Essential thrombocythemia 3 1.0
Nephrotic syndrome with cholesterol embolism 1 0.1
Immunological disease 24 16.0
Antiphospholipid syndrome (APS)b 5 3.3
Systematic lupus erythematosus (SLE) 2 1.3
Takayasu’s arteritis 10 6.7
Other systematic vasculitisc 7 4.7
Other causes of PAOD without thrombophilia 93 62
PAOD, Peripheral arterial obstructive disease.
a 1 case complicated with APS.
b 1 case complicated with systematic vasculitis.
c 1 case complicated with hyperhomocysteinemia.
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other factors such as inherited or acquired thrombophilia, trau-
matic or anatomical factors.3 The outcome of patients with
premature PAOD has been reported to be worse than that of their
older counterparts based on rapid progression of the disease and
a higher incidence of early bypass failures and amputations.2 This
may, in part, be due to an insufﬁcient awareness of the importance
of correctable aetiological factors which could lead to a signiﬁcant
delay of diagnosis and causative treatment of premature PAOD.
In particular, hypercoagulable states may be easily overlooked in
clinical practice, but are likely to affect outcome after surgical
revascularisation adversely.4 Thrombophilic abnormalities may
arise in the context of a variety of inherited or acquired immuno-
logical, myeloproliferative, inﬂammatory or coagulation cascade
disorders,5e10 all of which need to be looked for since these patients
with thrombophilia are at increased risk for early bypass failure,
frequently require multiple vascular interventions and have rela-
tively low limb salvage rates compared to patients with peripheral
vascular disease but without thrombophilia.10,11 This retrospective
analysis was undertaken to better understand aetiology proﬁle of
thrombophilia involved in premature PAOD in China, and to eval-
uate the inﬂuence of thrombophilia on the patency of the revas-
cularisations done in these young patients.
Materials and Methods
The medical records of all patients, less than 45 years of age and
presenting with symptomatic PAOD, but not attributed to Buerger’s
disease, to the vascular surgery department of Beijing Peking Union
Medical College between January 2000 and January 2010 were
reviewed. Patients were identiﬁed from the in-hospital and outpa-
tient databaseof PekingUnionMedical CollegeHospital. According to
our institutional protocol, patients who underwent serologic evalu-
ation for hypercoagulability were included in this study. The
following information was recorded for each patient: demographic
characteristics and vascular history including previous arterial
thrombo-embolic events or previous arterial reconstructions;
cardiovascular risk factors proﬁle including smoking, arterial hyper-
tension, hyperlipidaemia, diabetes mellitus, coronary artery disease,
cerebrovascular disease and other co-morbidities. In addition, PAOD
symptoms and vascular laboratory results at admission including
thrombophilia-screeningresultsandcharacteristicsof arterial lesions
were noted. Aetiology results and risk factor proﬁles were evaluated
in all patients including surgical and endovascular techniques used,
complications and outcomes of surgical reconstruction. Patients
suffering from thrombophilia were compared to those with normal
coagulation function. End points of the study were primary and
secondary patency rates of the arterial reconstruction and limb
salvage. Thepresentobservationalpost-hocanalysiswasapprovedby
the local ethics committee, and theneed for informedpatient consent
was waived as analysis was anonymised.
Deﬁnitions
The following deﬁnitions were used: symptomatic PAOD was
deﬁned as lower limb ischaemia with clinical manifestation
including intermittent claudication, rest pain or ischaemic tissue
loss, and details of the arterial lesions were identiﬁed by duplex
ultrasound or computer tomography angiogram (CTA). Symptoms
were considered acute, if symptoms appeared within 2 weeks
preceding admission in our institution. Conversely, symptoms that
persisted longer than 2 weeks were considered chronic PAOD.1
Deﬁnition of thrombophilia encompassed a series of inherited
and acquired hypercoagulable states including auto-immune
disorders, myeloproliferative states and others (Table 1).12Diagnosis was based on laboratory screening test results
including coagulation function assays such as prothrombin and
activated partial thromboplastin time; blood cell counts; erythro-
cyte sedimentation rates (ESRs) and level of C-reactive protein
(CRP); levels of protein C and S, antithrombin III, factor V Leiden,
prothrombin 20210A and homocysteine; as well as assays for lupus
anticoagulant, antiphospholipid and antinuclear antibodies (ANAs).
Perioperative management
Indication for treatment was based on the clinical evaluation
done by the vascular specialists in charge. In general, interventions
were considered for the patients with critical limb ischaemia (CLI)
or severe intermittent claudication (i.e., Rutherford category 3e6).
Patients with mild symptoms were managed by best medical
treatment, as long as symptoms responded satisfactorily. Patients,
in whom an immunological disorder has been detected, ﬁrst
received immunosuppressive therapy using oral prednisone and
cyclophosphamide for 1e3 weeks before surgery until inﬂamma-
tory markers (including ESR and CRP) returned to normal. In case of
acute limb-threatening ischaemia, immunosuppressive therapy
was started in the operating room. Patients with hyper-
homocysteinaemia received routinely folic acid and vitamin B12
supplements. In patients with myeloproliferative disorders such as
polycythaemia vera (PCV) or essential thrombocythaemia (ET),
hydroxyurea was administrated to reduce red blood cell mass and
platelet counts. Lastly, all patients received antithrombotic treat-
ment perioperatively according to the American College of Chest
Physicians (ACCP) guidelines.13 In brief, aspirin (100 mg d1) or
clopidogrel (75 mg d1) were used in patients without thrombo-
philia who underwent percutaneous transluminal angioplasty with
or without stenting. Patients with a hypercoagulable state, long-
segment occlusive lesions, poor distal outﬂow and those receiving
a below-knee surgical bypass received, in addition, warfarin. Low-
molecular-weight heparin (1 mg kg1 d1) was given until
patients reached the international normalised ratio (INR) long-
term target level between 2 and 3. All patients with hypercoagu-
lability or immunological disorders were advised to maintain on
speciﬁc drug therapy for at least 1 year.
Follow-up
Patients were followed at 1, 3, 6 and 12 months after discharge
and then on a yearly basis in an outpatient clinic. Interval history,
Table 2
Demographics characteristics and risk factors proﬁle of 150 patients with premature




test (n ¼ 93)
pb
Age (years)a 35 (32e41) 37 (30e42) 0.206c
Sex ratio (male:female) 48:9 73:20 0.390
Hypertension (%) 1 (2) 19 (20) 0.001
Diabetesmellitus (%) 1 (2) 10 (11) 0.040
Hyperlipidaemia (%) 6 (11) 21 (23) 0.062
Smoking (%) 28 (49) 39 (42) 0.390
Coronary arterial disease (%) 2 (4) 8 (9) 0.225
Cerebrovascular events (%) 2 (4) 6 (6) 0.436
Previous venous
thrombo-embolic disease (%)
2 (4) 3 (3) 0.925
Previous arterial
revascularization (%)
12 (21) 10 (11) 0.083
PAOD, peripheral arterial obstructive disease.
a Values are median (interquartile range).
b c2 test.
c ManneWhitney U test.
Table 3
Demographics characteristics and risk factors proﬁle of 108 patients with or without
thombophilia undergoing revascularization.
Characteristics Thrombophilia
group (n ¼ 38)
Normal coagulation
test group (n ¼ 70)
pb
Age (years)a 36 (32.5e41) 39 (32e42) 0.084c
Sex ratio 31:7 59:11 0.875
Hypertension (%) 6 (16) 8 (11) 0.519
Diabetes mellitus (%) 0 (0) 7 (10) 0.044
Hyperlipidaemia (%) 4 (11) 11 (16) 0.457
Smoking (%) 24 (63) 32 (46) 0.083
Coronary arterial disease (%) 0 (0) 5 (7) 0.092
Cerebrovascular events (%) 2 (5) 3 (4) 0.817
Previous arterial
revascularization (%)
10 (26) 5 (7) 0.006
Ipsilateral limb (%) 6 (16) 4 (6) 0.085
Contralateral limb (%) 4 (10) 1 (1) 0.032
PAOD, peripheral arterial obstructive disease.
a Values are median(interquartile range).
b c2 test.
c ManneWhitney U test.
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assess patency of the arterial reconstructions, limb salvage and
compliance with medication.
Statistical methods
Statistical analysis was performed using Statistical Package for
the Social Sciences (SPSS) 17.0 software. Continuous data were
expressed as median (interquartile range). Study groups were
compared using ManneWhitney U test for continuous data and
Pearson chi-square test for categorical data. Survival, patency and
limb salvage were analysed using the KaplaneMeier method and
compared by log-rank test. No imputation strategy was applied for
missing data points. All tests applied were unpaired and two-sided,
and a p-value of less than 0.05 was considered to indicate a statis-
tically signiﬁcant difference between groups.
Results
Of 368 patients, less than 45 years of age, with symptomatic
premature PAOD in our hospital database, evaluation records of 53
patients who suffered from Buerger’s disease and 165 patients
without thrombophilia did notmeet the inclusion criteria and were
excluded, leaving a total of 150 patients entered into the study.
Median age was 36 years (31.5e41.0 years). The median time
interval between onset of PAOD symptoms and admission was 3.2
months (1.5e6.0 months). At admission, 82 patients (55%) suffered
from severe and progressive claudication (Rutherford category 3),
19 patients (13%) presented with persistent rest pain (Rutherford
category 4) and 22 patients (15%) had ulceration or minor tissue
loss (Rutherford category 5). In another 27 patients (18%), the
indication for arterial reconstruction was acute limb-threatening
ischaemia (Rutherford Class 2) in the presence of underlying
peripheral arterial disease.
Aetiology, risk factors and location of lesions
Blood assays for thrombophilia were positive in 57 patients
(38%) and the remaining 93 patients were found to have no
abnormalities in thrombophilia evaluation. Of the 57 patients with
thrombophilia, hypercoagulable state mainly linked to haemato-
logical disorders was found in 33 patients (58%), 24 patients (42%)
suffered from immunological disease (Table 1). Prevalence of risk
factors varied according to the aetiology of premature PAOD. By
contrast, prevalence of hypertension (2 vs. 20%; p ¼ 0.001) and
diabetes (2 vs. 11%; p ¼ 0.040) was signiﬁcantly higher in normal
coagulation test group (Table 2). Arterial lesions were located in the
aorto-iliac segment in 27 patients (18%) and in the femoro-
popliteal-tibial segment in 70 patients (47%). Both segments were
affected in 53 patients (35%).
Treatment and outcome
A total of 42 patients were managed conservatively with
medical treatment only (28%), and the remaining 108 patients
(72%) underwent surgical or endovascular revascularisation
including 25 emergency procedures and 83 elective procedures
(Table 4). In 108 patients who underwent revascularisation, 38
patients (35%) were found with thrombophilia and the remaining
70 (65%) patients were found with normal coagulation test. Types
of arterial reconstruction according to study groups are detailed in
Table 4. The following comparisons of outcomes were performed
between patients with and without thrombophilia. Median length
of stay of operated patients was 23 days (13.5e28.0). Previous
revascularisation for both limbs salvage was more common inpatients with thrombophilia (26% vs. 7%; p ¼ 0.006), but redo
surgery rate on ipsilateral limb had no signiﬁcant difference
between the two groups (16% vs. 6%; p ¼ 0.085; Table 3).
There was no perioperative death, and the incidence of minor
complications was comparable between the two groups. Similarly,
involved arterial level and type of revascularisation were broadly
similar in the two groups (Table 4). However, emergency operations
occurred more often in the thrombophilia group (39% vs. 14%,
p¼ 0.003); and surgical embolectomywas performedmore often in
the patients with thrombophilia (68% vs. 47%, p ¼ 0.034; Table 4).
Recurrent thrombosis and major amputation within 30 days after
operation occurred more often in the thrombophilia group (29% vs.
9%; p ¼ 0.005), and (11% vs. 1%; p ¼ 0.032), respectively (Table 4).
Even if emergency procedures were excluded, early recurrent
thrombosis andmajor amputation rates remained more frequent in
the thrombophilia group (38.5% vs. 8.3%; p ¼ 0.004), and (23.1% vs.
1.7%; p ¼ 0.002), respectively.
Median duration of follow-up after revascularisation was 12
months (9e24 months). No patient died during follow-up. At 1
year, the primary patency rates (56% vs. 75%; ¼ 0.043, Fig. 1) and
secondary patency rates (68% vs. 92%; ¼ 0.036; Fig. 2) were poorer
in patients with thrombophilia. Similarly, limb salvage at 1 year was
lower in patients with thrombophilia (74% vs. 96%; p ¼ 0.038;
Fig. 3). Among the 38 patients with thrombophilia who received
a revascularisation, nine (24%) decided to stop the anticoagulant
Table 4
Surgical information and early outcomes of 108 patients with or without thombo-
philia undergoing revascularization.
Variables Thrombophilia
group (n ¼ 38)
Normal coagulation
test group (n ¼ 70)
pb
Indication
Limb salvage (%) 21 (55) 35 (50) 0.601
Claudication (%) 17 (45) 35 (50) 0.601
Location of lesion
Above-knee (%) 23 (61) 45 (64) 0.699
Below-knee (%) 15 (39) 25 (36) 0.699
Emergency operation (%) 15 (39) 10 (14) 0.003
Surgical procedures
Thrombectomy (%) 26 (68) 33 (47) 0.034
Bypass (%) 7 (18) 22 (31) 0.145
Endovascular intervention (%) 5 (13) 15 (21) 0.291
Minor complications
Wound infection (%) 1 (3) 0 (0) 0.173
Haematoma (%) 2 (5) 2 (3) 0.527
30-d reocclusion (%) 11 (29) 6 (9) 0.005
30-d amputation (%) 4 (11) 1(1) 0.032
Length of stay (days)a 24.5 (5e63) 21 (3e98) 0.128c
PAOD, peripheral arterial obstructive disease.
a Values are median (range).
b c2 test.
c ManneWhitney U test.
Figure 2. Cumulative secondary patency rate in patients undergoing surgical inter-
ventions with thombophilia factors (thrombophilia, n ¼ 38) and without (normal,
n ¼ 70). Difference in patency rate was statistically signiﬁcant with log-rank test
(p ¼ 0.003). All standard errors <10%.
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up and eight of them (89%) presented with recurrent thrombosis
during follow-up including six who required a major amputation
after failed revision. By contrast, among 29 thrombophilia patients
who remained compliant with the above treatment, only 11 (38%)
suffered recurrent thrombosis and received reoperation with six
major amputations during follow-up (p ¼ 0.008).
Out of 42 conservatively treated patients, 12 patients (29%) had
no condition for revascularisation because of no distal outﬂow, 13
(31%) refused any intervention, the remaining 17 (40%) who had
thrombophilia with active auto-immune or myeloproliferative
disorders needed special drug therapy to control the thrombo-
philia. Overall, 18 patients (43%) improved their symptoms under
medical treatment only, 16 (38%) were stable, and eight patients
(19%) including sevenwho had no operative condition and onewho
refused any operation worsened their symptoms and needed
a major amputation.Figure 1. Cumulative primary patency rate in patients undergoing surgical interven-
tions with thombophilia factors (thrombophilia, n ¼ 38) and without (normal, n ¼ 70).
Difference in patency rate was statistically signiﬁcant with log-rank test (p ¼ 0.024). All
standard errors <10%.Discussion
As in other parts of the world, recognition of premature PAOD in
young adults is often missed in China,3 probably because the aeti-
ology of premature PAOD is variable and may confuse early diag-
nosis and effective treatment. The present study aimed to lay out
the aetiological spectrum of premature PAOD, its clinical features
and treatment outcomes with a special focus on the impact of
thrombophilia on the prognosis. The key ﬁnding was that patients
with thrombophilia had the worst prognosis and that they needed
more re-interventions than patients with undisturbed coagulation.
This is particularly true if they did not adhere to the anticoagulant
and medical treatment of this condition.
Other studies have suggested that patients with premature
PAOD had rapid deterioration towards CLI due to repeated acute
thrombotic events and to a lack of collateral circulation.14 There-
fore, the prognosis of patients with premature PAOD was signiﬁ-
cantly worse than that of their older counterparts with an increased
rate of re-interventions, late amputation and overall poor long-Figure 3. Cumulative limb salvage rate in patients undergoing surgical interventions
with thombophilia factors (thrombophilia, n ¼ 38) and without (normal, n ¼ 70).
Difference in limb salvage rate was statistically signiﬁcant with log-rank test
(p ¼ 0.004). All standard errors <10%.
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studies, showing that a speciﬁc subset of patients, with a coagula-
tion disorder, might be partly responsible for the impaired outlook.
Reports in the European literature have shown that premature
PAOD was mostly associated with non-atherosclerotic disease such
as Buerger’s, collagen vascular disease, popliteal entrapment,
thrombo-embolism or vascular trauma.3 However, the role of
thrombophilia in this youngest subset of patients of less than 45
years was unclear. Ray et al.16 screened for thrombophilia a series of
124 patients with premature PAOD who had previously undergone
a lower limb revascularisation and found that 40% of them had some
kind of thrombophilia. The incidence of thrombophilia among non-
premature PAOD is lower than premature PAOD patients. Evans
et al.17 reported the incidence of thrombophilia in non-premature
PAOD patients as 21%. The prevalence seems to be similar in the
Chinese population, as almost 40% of patients referred to our
hospital for premature PAOD presented with thrombophilia that
could be attributed to either hypercoagulable states or immuno-
logical disorders. Therefore, although hypercoagulability has been
associated primarily with ‘idiopathic’ venous thrombo-embolic
disease in the past,14,16 it should also be recognised as an impor-
tant aetiological factor for arterial thrombo-embolism with an
increased risk of occlusion after arterial reconstructions.11,18,19
Thrombophilia may be inherited or acquired. The most impor-
tant inherited causes include genetic mutations of factor V Leiden
and factor IIG20210A, as well as deﬁcient antithrombin, protein C
and protein S, whereas acquired causes include lupus anticoagu-
lant/antiphospholipid antibody syndrome, myeloproliferative
disorders, essential thrombocytosis and nephrotic syndrome.5e9 In
our experience, most of the premature PAOD patients had acquired
thrombophilia based on myeloproliferative or immunological
disorders whereas inherited causes were rare. Vasculitis disorders
represent a further form of thrombophilia, in which endothelial
damage exposes extracellular matrix and activates the coagulation
system, especially during active inﬂammation.20,21 Therefore,
thrombophilia is a heterogeneous group of disorders and patients
with premature PAOD should be investigated thoroughly with
complete haematological, coagulation and serological proﬁles.22 In
our experience, primary serological test such as ESR and CRP should
be done in all the patients who had no clear reason for premature
PAOD. Furthermore, it is worthwhile to perform systematic and
extensive laboratory screening of thrombophilia in the patients
who had obvious hypercoagulable tendency such as repeat
thrombosis events, especially for the patients with positive results
in primary screening.
As shown in the literature, arterial revascularisation done in
patients with premature PAOD has been associated with poor
results,1 since PAOD progression is faster and the rate of failure after
bypass surgery is higher than in elderly patients. According to
Valentine et al.,2 29% of PAOD patients remain stable without
intervention and 29% remain stable for a mean of 76  13 months
after a single intervention. In comparison, 41% of young patients
with PAOD required multiple operations or major amputations
during the above follow-up period. Similar proportions were
observed in the present study. Thrombophilia may play an impor-
tant role in this context as it triples the risk of thrombotic occlusion
following arterial revascularisation.2 For instance, in our study,
every fourth patient with thrombophilia had already had
a previous arterial revascularisation in ipsilateral or contralateral
limb. Though this series of patients increased the bias of study
because theymay artiﬁcially increase the incidence of patients with
thrombophilia, it indirectly reﬂects that the patients with throm-
bophilia had higher thrombo-embolism events rate than the
normal population. In the thrombophilia group, the incidence of
thrombotic occlusions during follow-up was also much higher thanin patients without thrombophilia. Interestingly, these two groups
of patients with andwithout thrombophiliawere fairly similar with
regard to the other risk factors including indications, type of
revascularisation and medical treatment. This highlights the need
for complete investigations and careful surveillance of patients
with premature PAOD.
Potential limitations to our study include its retrospective
nature, and that this group of patients presenting with different
patterns of PAOD were heterogeneous and subjected to various
arterial reconstructive procedures. In addition, this was not a pop-
ulation-based study, but a single-centre experience with the risk of
recruitment bias. Another shortcoming is the lack of power for
confounder-adjusted analysis and subgroup analysis. Nonetheless,
the present study represents one of the largest series of premature
PAOD in which thrombophilia was consecutively assessed.
Conclusion
Thrombophilia is an important risk factor for patients with
premature PAOD in China. This is reﬂected by its high prevalence in
these young patients and its signiﬁcant negative impact on their
prognosis. This should encourage vascular specialists to screen
carefully these patients for thrombophilia, particularly, if the
patients had no clear reason for premature PAOD and with obvious
hypercoagulable tendency in clinical practice, because these
patients are likely to beneﬁt from a close follow-up with long-term
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